JMV2959

JMV2959 is a selective small molecule antagonist of the growth hormone secretagogue receptor 1A (GHSR1A), also known as the ghrelin receptor. By blocking this receptor, JMV2959 reduces the rewarding effects of drugs such as alcohol, cocaine, opioids, and methamphetamine in preclinical models, suppressing drug-seeking and cue-induced relapse. It also decreases ethanol and food intake in rodent studies. JMV2959 has been investigated as a potential therapy for substance use disorders—including alcohol dependence, opioid addiction, and stimulant addiction—and is not currently approved for any clinical indications. The compound was developed by an international collaboration involving researchers at the Institut des biomolécules Max Mousseron (France), Sahlgrenska Academy (Sweden), and AEterna Zentaris[1][2][3][4][5][6][7][8].

Other names

Ghrelin receptor antagonistJMV2959JMV-2959JMV 2959Growth hormone secretagogue receptor antagonistGHSR1a antagonistGHSR-1a antagonistGHSR 1a antagonistGH secretagogue receptor antagonist(R)-N-(2-(1H-indol-3-yl)-1-(4-(4-methoxybenzyl)-5-phenethyl-4H-1,2,4-triazol-3-yl)ethyl)-2-aminoacetamide hydrochloride